Table:
|  |  | Year Ended December 31, |  |
| --- | --- | --- | --- |
|  | 2019 | 2018 | 2017 |
|  |  | (In millions) |  |
| Cash and cash equivalents | $2,597 | $2,266 | $1,759 |
| Restricted cash | 10 | — | — |
| Short-term deposits | 4 | — | — |
| Marketable securities | 133 | 330 | 431 |
| Total financial resources | 2,744 | 2,596 | 2,190 |
| Short-term debt, including bank overdrafts | (173) | (146) | (118) |
| Long-term debt | (1,899) | (1,764) | (1,583) |
| Total financial debt | (2,072) | (1,910) | (1,701) |
| Net Financial Position | $672 | $686 | $489 |
Paragraphs:
Our Net Financial Position as of December 31, 2019 was a net cash position of $672 million, decreasing compared to the net cash position of $686 million at December 31, 2018.
At December 31, 2019, our financial debt was $2,072 million, composed of (i) $173 million of current portion of long-term debt and (ii) $1,899 million of long-term debt. The breakdown of our total financial debt included: (i) $1,354 million in the senior unsecured convertible bonds issued in 2017, (ii) $706 million in European Investment Bank loans (the “EIB Loans”), and (iii) $12 million in loans from other funding programs and other long-term loans.
The EIB Loans are comprised of three long-term amortizing credit facilities as part of our R&D funding programs. The first, signed in 2010, is a €350 million multi-currency loan to support our industrial and R&D programs. It was drawn mainly in U.S. dollars for an amount of $321 million and only partially in Euros for an amount of €100 million, of which $55 million remained outstanding as of December 31, 2019.
The second, signed in 2013, is a €350 million multi-currency loan which also supports our R&D programs. It was drawn in U.S. dollars for an amount of $471 million, of which $118 million is outstanding as of December 31, 2019. The third, signed in August 2017 for a total aggregate amount of €500 million in relation to R&D and capital expenditure investments in the European Union. It was fully drawn in Euros corresponding to $533 million outstanding as of December 31, 2019.
Question:
What was the increase / (decrease) in cash and cash equivalents from 2018 to 2019?
Answer: 2597 - 2266 = 331